Clinical global impression

The clinical global impression (CGI) rating scales are measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders.[1] It is a brief 3-item observer-rated scale that can be used in clinical practice as well as in researches to track symptom changes. It was developed by Early Clinical Drug Evaluation Program (ECDEU) team of researchers for use in NIMH-led clinical trials that could provide clinical judgment based assessment for determining the severity of symptoms and the treatment progress. This was meant to assess the patient's functioning prior to and after initiating medication in trials which is an important part of study process. Its 3 items assess, 1) Severity of Illness (CGI-S), 2) Global Improvement (CGI-I), and 3) Efficacy Index (CGI-E, which is a measure of treatment effect and side effects specific to drugs that were administered). Many researchers,[2][3] while recognizing the validity of the scale, consider it to be subjective as it requires the user of the scale to compare the subjects to typical patients in the clinician experience.

Validity of CGI scales

Despite its wider acceptance and consistent use in clinical trials, psychometric properties of CGI have not been established. However, the scale is found to be valid as an external criterion during the development of scales of depression and anxiety. In many studies, the clinicians' ratings of psychiatric symptoms were found to correlate significantly with self-rated and other valid scales of symptom severity. For example, Leon et al. (1993)[4] showed that severity ratings but not improvement ratings were predicted highly and significantly by frequency of panic attacks, depression and anxiety ratings made on already valid rating scales. Similarly, another study[5] showed that MADRS, HAM-D and CGI scales had comparable effect sizes and could be equally used in studies to assess severity and improvement of symptoms. Even though many studies have established the validity of CGI scales in relation to other commonly used robust rating scales, its efficacy in predicting treatment outcomes is highly debated. Its sensitivity is good enough to differentiate between responders and non-responders in clinical trials of depression,[6] but its specificity is not satisfactory. It has poor interrater reliability than HAM-D.[7] Many weaknesses could explain this possible lack of validity of the CGI: there is no specific interviewer guide available, and while most other symptoms scales have fairly clear and specific response options, the response format used in the CGI to assess change or severity of illness is more likely to be ambiguous (what is the definition of a patient who is "Severely ill"?).[8]

Severity scale

The clinical global impression – severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Clinicians ask: "Considering your total clinical experience with this particular population, how ill is the patient at this time?" Possible ratings are:[1]

  1. Normal, not at all ill
  2. Borderline mentally ill
  3. Mildly ill
  4. Moderately ill
  5. Markedly ill
  6. Severely ill
  7. Among the most extremely ill patients

Improvement scale

The clinical global impression – improvement scale (CGI-I) is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. Clinicians ask: "Compared to the patient's condition at baseline, this patient's [average] condition has...?" and rated as:[1]

  1. Very much improved
  2. Much improved
  3. Minimally improved
  4. No change
  5. Minimally worse
  6. Much worse
  7. Very much worse

Efficacy index

The clinical global impression – efficacy Index is a 4×4 rating scale that assesses the therapeutic effect of treatment with psychiatric medication and associated side effects.[1]

Therapeutic effect Side effects
None Do not significantly interfere with patient's functioning Significantly interfere with patient's functioning Outweigh therapeutic effect
Marked – Vast improvement. Complete or nearly complete remission of all symptoms
Moderate – Decided improvement. Partial remission of symptoms
Minimal – Slight improvement which doesn't alter status of care of patient
Unchanged or worse

See also

References
  1. Guy, William (1976). "Clinical Global Impressions". ECDEU Assessment Manual for Psychopharmacology—Revised. Rockville, MD: U.S. Department of Health, Education, and Welfare; Public Health Service, Alcohol; Drug Abuse, and Mental Health Administration; National Institute of Mental Health; Psychopharmacology Research Branch; Division of Extramural Research Programs. pp. 218-222. OCLC 2344751. DHEW Publ No ADM 76–338 – via Internet Archive.
  2. Samara, Myrto T.; Engel, Rolf R.; Millier, Aurelie; Kandenwein, Julia; Toumi, Mondher; Leucht, Stefan (November 2014). "Equipercentile linking of scales measuring functioning and symptoms: Examining the GAF, SOFAS, CGI-S, and PANSS". European Neuropsychopharmacology. 24 (11): 1767–1772. doi:10.1016/j.euroneuro.2014.08.009. PMID 25219937. S2CID 28853805.
  3. Suzuki, Takefumi; Uchida, Hiroyuki; Sakurai, Hitoshi; Ishizuki, Tomomi; Tsunoda, Kenichi; Takeuchi, Hiroyoshi; Mimura, Masaru (June 2015). "Relationships between global assessment of functioning and other rating scales in clinical trials for schizophrenia". Psychiatry Research. 227 (2–3): 265–269. doi:10.1016/j.psychres.2015.02.024. PMID 25882098. S2CID 6298832.
  4. Leon, A. C.; Shear, M. K.; Klerman, G. L.; Portera, L.; Rosenbaum, J. F.; Goldenberg, I. (1993). "A comparison of symptom determinants of patient and clinician global ratings in patients with panic disorder and depression". Journal of Clinical Psychopharmacology. 13 (5): 327–31. doi:10.1097/00004714-199310000-00005. PMID 8227491.
  5. Khan, A.; Khan, S. R.; Shankles, E. B.; Polissar, N. L. (2002). "Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials". International Clinical Psychopharmacology. 17 (6): 281–5. doi:10.1097/00004850-200211000-00003. PMID 12409681. S2CID 871694.
  6. Guelfi JD: Clinical research in psychopharmacology: new standards for drug development. An application to antidepressants. Psychiatrie et Psychobiologie. 1990, 5: 289-294
  7. Cicchetti DV, Prusoff BA: Reliability of depression and associated clinical symptoms. Arch Gen Psychiatry. 1983, 40: 987-990
  8. Kadouri, Alane; Corruble, Emmanuelle; Falissard, Bruno (2007). "The improved Clinical Global Impression Scale (ICGI): Development and validation in depression". BMC Psychiatry. 7: 7. doi:10.1186/1471-244X-7-7. PMC 1802073. PMID 17284321.
  • Guy, W. (2000). "Clinical Global Impressions (CGI) Scale, Modified". In Rush, John A.; Task Force for the Handbook of Psychiatric Measures (eds.). Handbook of Psychiatric Measures (1st ed.). Washington, DC: American Psychiatric Association. ISBN 978-0-89042-415-5. OCLC 43483679.

Public Domain This article incorporates public domain material from William Guy. ECDEU Assessment Manual for Psychopharmacology—Revised, 1976. National Institute of Mental Health.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.